The Masonic Cancer Center creates a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve quality of life for patients and survivors; and sharing its discoveries with other scientists, students, professionals, and the community. Founded in 1991, the cancer center became a National Cancer Institute-designated comprehensive cancer center in 1997, one of only 41 institutions in the United States and two in Minnesota to hold that designation.
More than 500 faculty and staff are members of the Masonic Cancer Center. It is home to some of the world's top cancer researchers in bone marrow transplantation, breast cancer, bone cancer, cancer genetics, tobacco research, immunology, new therapies development, pediatric oncology, chemoprevention, and epidemiology.
- Research is organized into seven programs that focus on specific themes.
- The Cancer Information Line 1-888-CANCER MN (1-888-226-2376) is available for residents of Minnesota, Iowa, North Dakota, South Dakota, and Wisconsin.
- Through clinical trials, researchers learn which approaches are more effective than others.
- Program meetings, seminars, and other interdisciplinary meetings at the Masonic Cancer Center brings together experts from different fields to address the problem of cancer.
- Members can apply for internal grant mechanisms available through the Masonic Cancer Center Internal Grants Program which is offered on an annual basis. The overall goal of this program is to foster the development of and provide support for novel research ideas that focus on a problem in cancer. In turn, the Cancer Center expects that these internal awards will lead to nationally peer reviewed funding.
News and Events
Drug developed at the Masonic Cancer Center with philanthropy's help finding early success
(Photo by Scott Streble) Daniel Vallera, Ph.D., took a risk when he retooled his Masonic Cancer Center research lab in 2000 to focus solely on producing cancer drugs. After all, this work is expensive, hard to fund, and has high liability. But the risk is paying off. Today, a drug he developed--brought to patients with the help of steadfast support from two philanthropists--is finding early success in clinical trials led by University of Minnesota colleague Veronika Bachanova, M.D., Ph.D. Read more.
Tobacco Research Studies
A new study to compare the effects of e-cigarettes versus regular cigarettes is underway at the University. For more information read the Health Talk Blog. For a list of all smoking studies and clinical trials, visit the Tobacco Research Program.
Update is an official newsletter of the Masonic Cancer Center for faculty, members, staff, colleagues, and friends.